Objective To investigate the effects of human bone marrow fibroblastoid stromal cell lines HFCL on the proliferation .migrating and homing of multiple myeloma cell lines RPM18226. Methods The co-culture system of RPMI8226 and HFCL was established through cell culture in vitro, growth curves were determined by trypan blue exclusion, cell cycle and expression of adhension molecule CD49d were detected by flow cytometry, and expression of CXCR4 gene was examined by RT-PCR. Results The proliferation of RPMI8226 cells in direct contact with HFCL cells group was inhibited strongerly than that in transwell group. The percentage of G1 phase cells of RPMI8226 cells in direct contact with HFCL group was higher than that of RPM 18226 in transwell group, while the percentage of S phase cells was lower. The expressions of CD49d and CXCR4 in RPMI8226 cells were down-regulated by HFCL cells, and that in transwell group was higher than that in direct contact with HFCL cells group. Conclusion Human bone marrow fibroblastoidss tromal cell HFCL can inhibit the proliferation and the expressions of CD49d and CXCR4 of multiple myeloma cell line RPMI8226, and can prevent multiple myeloma cells from migrating and homing.

Objective To investigate the effect of arsenic trioxide(As2O3) on the biology characteristics of multiple myeloma RPMI8226 cells in vitro and the molecular mechanism.Methods Multiple myeloma RPMI8226 cells were used for experiments target,cell cycle,apoptotic peak,and adhesion molecular VLA4(CD49d) were determinded by flow cytometry.Expression of CXCR4gene was examined by RT-PCR.Expression of death receptor DR4 and DR5 were measured by immunofluorescence microscopy and flow cytometry.Results Five ?mol/L As2O3 upregulated DR4 and DR5 expression on RPMI8226 cells markedly(P

Objective To investigate the efficacy and safety of fludarabine cytarabine and granulocyte colony stimulating factor (FLAG) chemotherapy on adult relapsed or refractory adult acute lymphoblastic leukemia (ALL) patients.Methods Twenty adult patients with relapsed or refractory ALL were treated with salvage therapy which was combined of fludarabine,cytarabine and granulocyte colony stimulating factor (FLAG).Another 20 cases in control group were treated with primal induction regimen and idamycin combined with etoposide and high-dose methylprednisolone.Sides effects of 2 groups were compared and FCM was used to investigate the cells with leukemia associated with immunophenotype,final comparing with bone marrow morphology.Results Hematologic toxicity was similar both in the treatment group and control group.Nonhematology complications consisted of heart and liver toxicity (1/20 and 9/20) were weaker than those in control group (4/20 and 1/20),which were mild to moderate and could be alleviated with supportive therapy.The median overall survival was no significant difference between both sides,eights patients (40.0 ％) who achieved complete remission received salvage therapy,the disease-free survival and the median overall survival were 6 months (range 4-30 months) and 11 months (range 9-30 months),respectively.Seven patients (35.0 ％) achieved complete remission in the treatment group,the disease-free survival and the median overall survival were 4 months (range 3-30 months) and 9 months (range 9-30 months) for 7 patients,respectively.In the treatment group early recurrence [5.0 ％ (1/20)] and outside marrow of recurrence rate (0)were lower than in control group [20.0 ％ (4/20) and 10.0 ％ (2/20)].Conclusion FLAG is a well-tolerated regimen for adult relapsed or refractory ALL patients which enables patients to receive allogeneic stem cell transplantation.